Zhiwei Li

Prof. Zhiwei Li

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2024 in Advanced Science
Verified
Journal Article
Open access
XFXiaona Fan
Xiaona Fan
YDYisheng Dai
Yisheng Dai
CMChuanfeng Mo
Chuanfeng Mo
HLHengzhen Li
Hengzhen Li
XLXindi Luan
Xindi Luan
ZLZhiwei Li
Zhiwei Li
Pancreatic cancer (PC) progresses rapidly, and gemcitabine‐based chemotherapy has brought only limited efficacy. Identifying key drivers and therapeutic targets holds significant clinical value. In this study, through comprehensive analysis of multiple PC databases, this work identifies TRIM21 as a promising driver mediator. This work further performs loss‐ and gain‐of‐function assays for TRIM21, revealing that TRIM21 knockout inhibits tumor proliferation and gemcitabine resistance both in vitro and vivo. Lipidomics reveal that silencing TRIM21 reduce the arachidonic acid production, and inhibit ferroptosis. Mechanically, through proteomics, ubiquitomics, and liquid chromatography‐tandem mass spectrometry analysis, the key metabolic enzyme of arachidonic acid ‐EPHX1 is identified as a downstream substrate of TRIM21. TRIM21 interacts with EPHX1 through its SPRY domain and promotes ubiquitin‐mediated degradation of EPHX1 via K33‐ and K48‐linked ubiquitination at the K105 site. Given the targeting potential, this work screens Bezafibrate to block the interaction between TRIM21 and EPHX1 and validates its sensitizing effect. In summary, TRIM21 promotes tumour growth and gemcitabine resistance in PC by inhibiting EPHX1‐mediated arachidonic acid metabolism. This provides a novel and promising target for clinical treatment of PC.

10 April 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
HLHengzhen Li
Hengzhen Li
YRYuli Ruan
Yuli Ruan
CLChao Liu
Chao Liu
XFXiaona Fan
Xiaona Fan
YYYuanfei Yao
Yuanfei Yao
ZLZhiwei Li
Zhiwei Li
Background: Activation of VDR pathway was a promising anti-tumor therapy strategy. However, numerous clinical studies have demonstrated the effect of activating VDR is limited, which indicates that VDR plays a complex role in vivos. Methods: We analyzed the TCGA database to examine the association between VDR expression and immune cell infiltration in pancreatic adenocarcinoma (PAAD). Western blot, ELISA, ChIP, and dual-luciferase reporter assays were performed to determine the mechanism of VDR regulating CCL20. Migration assay and immunofluorescence were used to investigate the role of CCL20 in M2 macrophage polarization and recruitment. We employed multiplexed immunohistochemical staining and mouse models to validate the correlation of VDR on macrophages infiltration in PAAD. Flow cytometry analysis of M2/M1 ratio in subcutaneous graft tumors. Results: VDR is extensively expressed in PAAD, and patients with elevated VDR levels exhibited a significantly reduced overall survival. VDR expression in PAAD tissues was associated with increased M2 macrophages infiltration. PAAD cells overexpressing VDR promote macrophages polarization towards M2 phenotype and recruitment in vitro and vivo. Mechanistically, VDR binds to the CCL20 promoter and up-regulates its transcription. The effects of polarization and recruitment on macrophages can be rescued by blocking CCL20. Finally, the relationship between VDR and M2 macrophages infiltration was evaluated using clinical cohort and subcutaneous graft tumors. A positive correlation was demonstrated between VDR/CCL20/CD163 in PAAD tissues and mouse models. Conclusion: High expression of VDR in PAAD promotes M2 macrophage polarization and recruitment through the secretion of CCL20, which activates tumor progression. This finding suggests that the combination of anti-macrophage therapy may improve the efficacy of VDR activation therapy in PAAD.

1 January 2026 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
MLMing Liang
Ming Liang
SYShengjie Yin
Shengjie Yin
YDYisheng Dai
Yisheng Dai
FXFan Xu
Fan Xu
BCBowen Chang
Bowen Chang
TWTianzhen Wang
Tianzhen Wang
Vitamin D (VD) has been the focus of extensive clinical research, yet conclusions regarding its biological roles remain inconsistent. VD exerts its functions through the vitamin D receptor (VDR), a nuclear transcription factor that regulates the expression of VD3-responsive target genes. Notably, divergent findings across studies have been reported regarding VDR expression patterns and functional roles, underscoring the complexity of VDR in cancer biology. Whether this complexity interferes with VD’s biological activity-thereby contributing to the variable impacts of VD3 on cancer prevention and treatment-remains unclear. This review systematically addresses: (1) the association between VDR expression (assessed by immunohistochemistry) and cancer prognosis; (2) the roles and mechanisms of VDR in cancer; (3) the multi-level regulatory networks governing VDR expression and activity; and (4) the translational implications of VDR in cancer therapy. Elucidating the precise roles and mechanisms of VDR is critical for optimizing cancer treatment strategies and resolving conflicting clinical evidence.

3 September 2024 in The Oncologist
Verified
Journal Article
Open access
ZLZhiwei Li
Zhiwei Li
XFXiaona Fan
Xiaona Fan
DJDan Jiang
Dan Jiang
QLQingwei Li
Qingwei Li
CLChao Liu
Chao Liu
YZYanqiao Zhang
Yanqiao Zhang
Background: Alternating sequential administration of drugs may be a promising approach to overcome chemotherapy resistance in advanced pancreatic ductal adenocarcinoma (PDAC). Methods: This study was an open-label, single-arm, and prospective trial included patients with untreated advanced PDAC. They received 2 cycles of NS regimen (nab-paclitaxel:125 mg/m2, intravenously injected on days 1 and 8, plus S-1:40-60 mg, orally twice per day for 1-14 days) followed by 2 cycles of GemOx regimen (gemcitabine, intravenously injected on days 1 and 8, and oxaliplatin: 130 mg/m2, intravenously injected on day 1). The primary efficacy endpoint was a progression-free survival rate at 6 months (PFSR-6m). The secondary efficacy endpoints included overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Specific mRNA transcripts were used to explore survival associated genes. Results: Forty-two patients received a minimum of one treatment cycle, and of these, 30 patients completed one alternating treatment consisting of 4 cycles. The PFSR-6m was 71% (95% CI = 58%-87%). The median PFS and OS were 6.53 months (95% CI = 6.03-8.43) and 11.4 months (95% CI = 9.8-14.4), respectively. Common grades 3-4 hematological AEs included neutropenia 30.9%, leukopenia 26.2%, anemia 2.4%, and thrombocytopenia in 11.9%. Patients with OS > 10 months showed high expression of HLA-DQA2 while melanoma-associated antigen genes (MAGE) were notably upregulated in patients with OS < 10 months. Conclusion: The alternating sequential administration of the NS and GemOx regimens may be a novel approach for first-line chemotherapy in patients with advanced PDAC requiring further study (ClinicalTrials.gov Identifier: ChiCTR1900024867).

10 December 2025 in Journal of Advanced Research
Verified
Journal Article
Open access
HLHengzhen Li
Hengzhen Li
MCMeng Chen
Meng Chen
YLYing Liu
Ying Liu
HTHaimeng Tang
Haimeng Tang
GJGuangtao Jiao
Guangtao Jiao
ZLZhiwei Li
Zhiwei Li
Gastric cancer remains a major global health burden, with high mortality driven by late-stage diagnoses that limit treatment options and reduce survival. Current diagnostic methods such as endoscopy and biopsy are invasive, resource-intensive, and impractical for large-scale early detection. This study aimed to develop and validate an ensemble machine learning model integrating four cell-free DNA (cfDNA) fragmentomic feature classes derived from 5 × whole genome sequencing (WGS) data to non-invasively differentiate malignant gastric cancer from benign gastric lesions in high-risk or symptomatic patients. A total of 681 plasma samples were prospectively collected, comprising 329 from patients with gastric cancer or high-grade intraepithelial neoplasia (HGIN) and 352 from individuals with benign gastric conditions. The dataset was divided into a training cohort (n = 333) and a temporally independent validation cohort (n = 348). An external validation cohort of 305 participants was also included. The ensemble model achieved an AUROC of 0.920 in cross-validation testing on the training cohort, 0.912 in the independent validation cohort, and 0.896 (95% CI 0.860-0.932) in the external cohort. At a pre-specified prediction threshold of 0.402, the model demonstrated 93.3% sensitivity and 71.9% specificity in the validation cohort, yielding a PPV of 71.3% and an NPV of 93.5%. In the external cohort, sensitivity and specificity were 91.7% and 69.1%, respectively (PPV 75.7%, NPV 88.8%). Model scores correlated with clinical stage, tumor grade, and histopathological subtype. Approximately 71% of non-cancer patients could have been spared unnecessary endoscopy. The cfDNA fragmentomics-based ensemble model enables accurate, non-invasive differentiation between gastric cancer and benign gastric lesions in high-risk or symptomatic patients. This approach demonstrates strong potential as a pre-endoscopy triage tool, supporting earlier detection and more efficient use of diagnostic resources.

1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
DMDazhuang Miao
Dazhuang Miao
YSYushui Song
Yushui Song
LZLiang Zhou
Liang Zhou
GLGuanying Liang
Guanying Liang
YWYan Wang
Yan Wang
JTJinxue Tong
Jinxue Tong
Background: Autophagy has a critical involvement in the initiation and progression of various cancers, including colorectal cancer (CRC). The feasibility of using autophagy‐related genes (ATGs) as prognostic tools for CRC patients is yet to be determined. Methods: RNA sequencing data and clinical information for CRC were obtained from The Cancer Genome Atlas (TCGA) (training set) and Gene Expression Omnibus (GEO) datasets GSE39582 and GSE44076 (validation). ARGs were retrieved from the Human Autophagy Database, and differentially expressed ARGs (DAGs) were identified using the “limma” R package. Prognostic signature DAGs were established via univariate Cox and LASSO Cox regression analyses. The obtained signature was validated through expression analysis, autophagy scoring, survival prediction, and correlation with immune status. Immunohistochemistry assays and in vitro functional experiments in SW480 cells were performed to assess the biological roles of selected DAGs, particularly WIPI2. Results: We constructed an 11‐gene prognostic signature (CANX, NRG1, WIPI1, EIF2AK3, WDR45, PELP1, ULK1, WIPI2, DAPK1, ULK3, and MAP1LC3C), with high‐risk patients showing significantly reduced overall survival compared to low‐risk patients. WIPI2, highly expressed in SW480 cells, was selected for functional validation. Knockdown of WIPI2 inhibited cell proliferation, suppressed autophagy (decreased LC3B‐II, increased p62), and promoted apoptosis (increased cleaved caspase‐3). These findings confirm the pro‐survival role of WIPI2 in CRC. The prognostic signature remained independently predictive after adjusting for clinical factors and showed a strong correlation with immune infiltration in TCGA CRC samples. Conclusion: The autophagy‐related signature independently predicts CRC prognosis and guides immunotherapy strategies.